PMID- 21592611
OWN - NLM
STAT- MEDLINE
DCOM- 20120306
LR  - 20220310
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 74
IP  - 3
DP  - 2011 Dec
TI  - Comparison of treatment costs of grade 3/4 adverse events associated with 
      erlotinib or pemetrexed maintenance therapy for patients with advanced 
      non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
PG  - 529-34
LID - 10.1016/j.lungcan.2011.04.010 [doi]
AB  - Objective of this indirect economic comparison was to estimate and compare 
      management costs of grade 3/4 adverse events (AEs) reported for first-line 
      erlotinib or pemetrexed maintenance therapy in patients with advanced non-small 
      cell lung cancer (NSCLC). The economic analysis was performed for Germany, 
      France, Italy and Spain. Types and incidences of reported grade 3/4 AEs observed 
      with erlotinib or pemetrexed maintenance therapy were retrieved from two recently 
      published placebo-controlled trials. Country-specific estimates on standard 
      treatment algorithms and incremental medical resource utilization associated with 
      each of the reported grade 3/4 AEs have been obtained from clinical oncologists 
      practicing in the four countries and co-authoring this article. The resource use 
      items were subsequently assigned country-specific tariffs to estimate total 
      per-patients costs associated with the AE profiles of the two compared 
      maintenance regimens. For the economic analysis a customized economic spreadsheet 
      model was employed. Our comparison shows lower total average per-patient AE 
      management costs for erlotinib than for pemetrexed maintenance therapy in all 
      four studied countries. Total estimated cost savings per patient in favour of 
      erlotinib amount to euro 121, euro 237, euro 106, and euro 119 for Germany, France, Italy and 
      Spain, respectively. These AE cost savings for erlotinib when compared to 
      pemetrexed represent a decrease by 80%, 71%, 94%, and 82%, respectively. The 
      study also discovered considerable differences in AE management costs across 
      countries which are primarily due to differences in clinician's estimates of 
      hospitalization referral rates. Erlotinib maintenance therapy in patients with 
      advanced NSCLC causes lower AE management costs than pemetrexed maintenance 
      therapy indicating a potentially superior tolerability profile.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Banz, Kurt
AU  - Banz K
AD  - Outcomes International, Basel, Switzerland. kurt.banz@outcomes.ch
FAU - Bischoff, Helge
AU  - Bischoff H
FAU - Brunner, Matthias
AU  - Brunner M
FAU - Chouaid, Christos
AU  - Chouaid C
FAU - de Castro Carpeno, Javier
AU  - de Castro Carpeno J
FAU - de Marinis, Filippo
AU  - de Marinis F
FAU - Grossi, Francesco
AU  - Grossi F
FAU - Vergnenegre, Alain
AU  - Vergnenegre A
FAU - Walzer, Stefan
AU  - Walzer S
LA  - eng
PT  - Journal Article
DEP - 20110517
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Glutamates)
RN  - 0 (Quinazolines)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 5Z93L87A1R (Guanine)
RN  - DA87705X9K (Erlotinib Hydrochloride)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*economics/pathology/physiopathology
MH  - Erlotinib Hydrochloride
MH  - France
MH  - Germany
MH  - Glutamates
MH  - Guanine/analogs & derivatives
MH  - Italy
MH  - Pemetrexed
MH  - Quinazolines
MH  - Spain
EDAT- 2011/05/20 06:00
MHDA- 2012/03/07 06:00
CRDT- 2011/05/20 06:00
PHST- 2011/01/14 00:00 [received]
PHST- 2011/03/17 00:00 [revised]
PHST- 2011/04/16 00:00 [accepted]
PHST- 2011/05/20 06:00 [entrez]
PHST- 2011/05/20 06:00 [pubmed]
PHST- 2012/03/07 06:00 [medline]
AID - S0169-5002(11)00255-8 [pii]
AID - 10.1016/j.lungcan.2011.04.010 [doi]
PST - ppublish
SO  - Lung Cancer. 2011 Dec;74(3):529-34. doi: 10.1016/j.lungcan.2011.04.010. Epub 2011 
      May 17.